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Highlights 
 
► Human Papillomavirus vaccination demands urgent attention. ► The cost-effectiveness 
of including boys into HPV vaccination programs should be re-assessed. ► Steps must be 
taken to achieve the target of universal vaccination. ► There is sufficient evidence to urge 
the EU Community to eradicate all HPV related cancers. ► Policymakers must consider 
effective vaccination programs in the prevention of cancers. 
Abstract  
Background: The story of Human Papillomavirus vaccination demands reflection not only 
for its public health impact on the prophylactic management of HPV disease, but also for 
its relevant economic and social outcomes. Greater than ever data confirm the efficacy 
and support the urge for effective vaccination plans for both genders before sexual debut.  
Methods: A review of previous experience in gender-restricted vaccination programs has 
demonstrated a lower effectiveness. Limiting vaccination to women might increase the 
psychological burden on women by confirming a perceived inequality between genders; 
and even if all women were immunized, the HPV chain of transmission would still be 
maintained through men. 
Results: The cost-effectiveness of including boys into HPV vaccination programs should 
be re-assessed in view of the progressive drop of the economic burden of HPV-related 
diseases in men and women due to universal vaccination. The cost of the remarkable 
increase in anal and oropharyngeal HPV driven cancers in both sexes has been grossly  
underestimated or ignored. Conclusions: Steps must be taken by relevant bodies to 
achieve the target of universal vaccination. The analysis of HPV vaccination’s clinical 
effectiveness vs. economic efficacy are supportive of the economic sustainability of 
vaccination programs both in women and men. 
In Europe these achievements demand urgent attention to the social equity for both 
genders in healthcare. There is sufficient ethical, scientific, strategic and economic 
evidence to urge the European Community to develop and implement a coordinated and 
comprehensive strategy aimed at both genders and geographically balanced, to eradicate 
cervical cancer and other diseases caused by HPV in Europe. 
Policymakers must take into consideration effective vaccination programs in the prevention 
of cancers. 
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1. Clinical Prospects on Efficacy  
1.1. HPV vaccines today 
Until recently, HPV infection with high risk or oncogenic HPVs seemed to correlate solely 
to cervical carcinoma, while today it is known to be primarily responsible for cancerous and 
precancerous lesions of the ano-genital area in both males and females; it is also 
responsible, at a lower but not negligible rate, for head and neck cancers (1). HPV was 
ascribed to cause effectively 100% of cervical cancer cases, 88% of anal cancer cases, 
43% of vulvar cancer cases, 70% of invasive vaginal carcinomas, 50% of all penile 
cancers worldwide (2). The exact proportion in Head and Neck (H&N) cancer is unknown 
but the anatomical site specific cancer “oropharyngeal squamous cell carcinoma 
(OPSCC)” is increasing in the UK (were data are  available) at a rate of 15% per annum. In 
England, USA and Canada around 70% of OPSCC is thought to be HPV driven, and 
oropharyngeal cancer constitutes about one third of the over 9000 cases of H&N cancer in 
England in Wales per annum (3). It is unclear why the dramatic increase in both 
oropharyngeal and anal cancer driven by HPV affecting both sexes which now exceeds 
the incidence of cervical cancer has received so little attention from policymakers (4).  
One third of HPV-16 and HPV-18-induced cancers in Europe (5) and the US (6) appears 
to affect men, while low-risk viruses such as HPV-6 and -11 cause genital warts, 
representing a huge disease burden in both men and women (7). Squamous cell cancers 
of the oral cavity (OCC) and of the oropharynx (OPSCC) are the sixth most prevalent 
cancers worldwide with an estimated 400.000 cases per annum and 230.000 deaths (8): 
around 30% of these are estimated to be caused by HPV. Currently a three-yearly smear 
test is recommended for women aged 21 to 29; HPV testing is not recommended in this 
age group since HPV infections are common during the second decade of life (although 
they do not persist in most cases) (9). For women, aged 30 to 65, 3-yearly cytology 
screening is recommended or 5-yearly cotesting (Pap smear + HPV test) (9). Although 
already approved only in the Netherlands, most of European countries are moving to 
cervical cancer screening with primary HPV-DNA test, with further cytological triage if 
necessary. There are no screening programs for all other HPV related cancers in both 
men and women.  
In males, the quadrivalent HPV (qHPV) vaccine efficacy against ano-genital lesions related 
to HPV 6,11,16 and 18 has been reported by Giuliano et al (10[0]) up to 90% in per-
protocol (PP) population and 65.5% in intention-to-treat (ITT) group. In the same study, 
vaccine efficacy against persistent incident infection and HPV-DNA detection was 47.8% 
and 27.1% in PP and ITT population, respectively. 
 
 
Both vaccines (Table 1.) are considered highly effective against cervical cancer and pre-
cancerous lesions caused by HPV 16 and 18. Both vaccines provide some cross-
protection against HPV genotypes which are not included in the vaccines (13). The 
increased importance of vaccinating both girls and boys is underlined by the mostly low 
coverage of national, girls-only vaccination programs (14). The European Centre for 
Disease Prevention and Control (ECDC) acknowledged that the most effective strategy to 
prevent HPV-related morbidity would be universal coverage of both females and males 
(15). 
Cross-protection against non-vaccine HPV types is an important consideration since non-
vaccine HPV types are associated with 30% approximately of cervical cancer (16). Data 
on cross-protection against persistent infection and against disease endpoints are not 
easy to be evaluated so far for the differences in the experimental approaches and 
differences in the evaluation of efficacy results (16). Furthermore, data from clinical studies 
show that the supposed cross-protection specially against non-vaccine HPV types 31, and 
45, decreases during an increased follow-up, suggesting a waning of cross-protection (17). 
 
1.2. New vaccine against HPV-diseases  
The 9vHPV (nine-valent or nonavalent) vaccine, recently approved in a fast track by FDA 
on December 2014, and in Europe by EMA first approval given by CHMP the 27th of March 
2015 and approved finally on 10/06/2015 (18) it is expected to prevent compared to 
bivalent and quadrivalent vaccine from 40% to 70% of CIN2, from 58% to 84% of CIN3, 
and from 90% to 94% of AIS (adenocarcinoma in situ): these data have been highlighted 
by Joste et alii after they analyzed a population-based sample of 6.272 tissue specimens 
tested for HPV genotypes (19). In a total of 14,215 randomized participants  population the 
9vHPV vaccine has been studied: this study showed that the 9vHPV vaccine prevented 
cervical, vulvar, and vaginal disease and persistent infection associated with HPV-31,-33,-
45,-52, and-58, and generated antibody response to HPV-6,-11,-16, and-18 that was not 
inferior to that generated by the qHPV vaccine. The 9vHPV vaccine did not prevent 
infection and disease related to HPV types beyond the nine types covered by the vaccine 
(20).  
Changing from a bivalent or quadrivalent to a nonavalent HPV vaccine is predicted to 
reduce the cumulative number of anogenital warts (AGWs) episodes by an additional 
66.7% (compared with bivalent) or 0.0% (compared with quadrivalent), CIN2 and CIN3 
episodes by an additional 9.3% (compared with bivalent) or 12.5% (compared with 
quadrivalent), and squamous cell carcinoma (SCC) cases by an additional 4.8% 
(compared with bivalent vaccine) or 6.6% (compared with quadrivalent vaccine) in the 
cumulative incidence up to 70 years (21).  
The potential impact of 9vHPV vaccine (22) estimated through the relative contribution 
(RC) towards invasive cervical cancer (ICC) and the precancerous cervical lesions of the 
nine HPV types in ICC, was 89.4% and varied by histology, ranging between 89.1% in 
SCC and 95.5% in adenocarcinomas (ADC). The overall safety profile of the 9vHPV 
vaccine was comparable to the qHPV vaccine (23) across multiple studies and different 
populations. Few multinational studies show (24) how vaccines protective against HPV-16 
and HPV-18 could potentially prevent 44.702 cases (79%) of ADC per year, assuming 
100% vaccine coverage. An efficacy and immunogenicity study of 9vHPV vaccine (25) 
conducted in young women from 16 to 26 years of age demonstrates that the 
immunogenicity of 9vHPV vaccine is non-inferior to that of qHPV vaccine; it was also 
demonstrated how 9vHPV vaccine is highly effective when compared to qHPV vaccine in 
preventing HPV-31,-33,34,-52,-58-related persistent infections and conditions.  
 
1.3. Anogenital warts 
Genital Warts-GWs are part of a hidden world which is not overtly targeted by national 
health plans; patients are thus obliged to hide their condition. In some countries, such as in 
Italy, their treatment is thus missing from epidemiology databases and economic records. 
Mariani et alii (26) identified 13 publications from 9 sources in 6 countries (Australia, New 
Zealand, US, Denmark, Germany and Sweden) revealing the real-world impact of qHPV 
vaccine on the incidence of GWs. These results provide evidence for a rapid, strong 
impact on GW incidence in vaccine-target populations and a smaller, but substantial, 
indirect impact in non-targeted populations. These data have been further confirmed by 
Hariri et alii (27): about 90% of cases of GWs were caused by HPV-6 and -11 (28). 
Reductions in the incidence of genital warts have been documented in several countries, 
depending on the level of coverage with qHPV vaccine.   
2. Safety 
The WHO Global Advisory Committee for Vaccine Safety (GACVS) has regularly reviewed 
the evidence on the safety of HPV vaccines.  
 
 
Local reactions: injection site reactions included pain (92.9% bivalent, 71.6% 
quadrivalent), redness (44.3% bivalent, 25.6% quadrivalent) and swelling (36.5% bivalent, 
21.8% quadrivalent) (31). In both vaccines injection site reactions, particularly pain, are 
usually of short duration and resolve spontaneously (32). 
Systemic reactions: pyrexia, headache, dizziness, myalgia, arthralgia are observed. Post-
vaccination syncope has been reported, as for many other vaccines, but can be minimized 
and its complications avoided with appropriate care (32). 
In pre-licensure trials of the quadrivalent vaccine (33), in vaccine recipients not already 
infected with HPV, systemic adverse events were monitored for the first 15 days post 
vaccination. Pyrexia was the only reported adverse event that occurred in >10% of 
vaccinees and more frequently than in placebo groups (10.1% and 8.4%, respectively). 
In post-licensure clinical trials which enrolled 997.585 girls aged 10-17 years old, no 
serious adverse events ascribable to the vaccine were recorded for the quadrivalent as 
well as the bivalent vaccine (34). 
In post-licensure clinical trials a review of post-licensure safety surveillance during > 4 
years of routine use of the bivalent vaccine found no patterns or trends for potential 
immune-mediated diseases after vaccination (35). 
Pregnancy: in the absence of well-controlled studies in pregnant women, vaccination with 
HPV vaccine is not recommended in pregnancy as a precautionary measure. However, 
some data are available from pregnant women inadvertently enrolled in Phase III clinical 
trials with known pregnancy outcomes, and through the establishment of pregnancy 
registers. The rate of major congenital anomalies was within the expected background 
population rate of 2–3%. No trends were observed, and the rate of spontaneous abortion 
was in line with reported rates in the UK and USA (35). 
The 9vHPV vaccine was generally well tolerated among women aged 16–26 years and 
boys/girls aged 9–15 years. Vaccine-related serious adverse experiences (SAEs) were 
rare. The 9vHPV vaccine displayed an adverse event profile generally comparable to that 
of 4vHPV. Vaccine-related adverse experiences (AEs) were largely ascribable to injection-
site experiences, most of which were of mild or moderate intensity. These considerations 
were based on 3.066 boys and girls (36), 600 boys and girls (37) and 14.204 women aged 
16-26 and 3.011 preadolescent and adolescent boys and girls (age 9-15) (38).  
Case reports have suggested a link between human papillomavirus (HPV) vaccination and 
development of multiple sclerosis and other demyelinating diseases. Scheller et alii with 
their study have demonstrated that qHPV vaccination was not associated with the 
development of multiple sclerosis or other demyelinating diseases. These findings do not 
support concerns about a causal relationship between qHPV vaccination and 
demyelinating diseases (39).   
3. Economic evaluation    
3.1. Recommended immunization 
The recommended immunization schedule for HPV by the European Center for Disease 
Control and Prevention - ECDC is presented in the Table 3. 
 
Table 3.   
The European Vaccine Schedule at the start of 2015, as it is in the European Center for 
Disease Control and Prevention-ECDC and in other publications.   
 Gender  Ages of 
Vaccination 
Doses  Notes  
Austria F & M  10 and 13 
9 and 12 
2  Boys and Girls. Free of charge in 
school programs. At 13 years partially 
subsidized. 
http://bmg.gv.at/cms/home/attachmen
ts/8/9/4/CH1100/CMS138936586001
3/impfplan.pdf. Vienna, January 2015 
New vaccination calendar 01/2014 
http://bmg.gv.at/cms/home/attachmen
ts/8/9/4/CH1100/CMS138936586001
3/impfplan2014.pdf  
Belgium  F 10 3 Recommended for girls 10-13 years 
old with 3 doses (schedule 0, 1, 6 
months (2vHPV) or 0, 2, 6 months 
(4vHPV) 
 
 
 
Bulgaria F 12  HPV vaccination is not included in the 
National Immunization schedule. The 
vaccination is voluntary, but free of 
charge for 12-year-old girls 
Croatia     
Cyprus     
Czeck Rep F 13 and 18 3 Recommended only Females only. 
Three doses 
Denmark F 12 and 19  Females only. Denmark’s childhood 
vaccination program 2014t.d 
Danish Health and Medicines Authority 
Estonia      
Finland  F 11 and 13  HPV catch-up during the first 2 years 
of introduction to girls 13-15 years of 
age 
France F 11 and 15  2 and 3 11 to 13/14  2 doses  
Three doses in a 0, 1 or 2, 6 month 
schedule (girls aged 15 to 19 years) 
Haut Conseil de la santé publique 
Germany F 9 to 13/14 
and 15  
2 and 3 Two doses at 6 months interval. 
Females only. If the interval between 
two doses is < 6 months,  a 3rd dose 
may be recommended  
Empfehlungen der Standigen 
Impfkommission (STIKO) am Robert 
Koch-Institut/Stand: August 2014 
Greece F 11 and 19 2 and 3 Females only. Vaccination 
recommended up to 26 years of age 
from January 2015 New NVC 
01/2015 (2D in girls 11 to <15 yo) 
Hungary     
Iceland F 12  Females only. 7th grade 
Ireland F 11 2 and 3 First year second-level school 
(females 12 to 13 years of age), 3 
doses given between 6-12  months 
NIAC 08/2014 (2D Girls 9-<15y; 0-6 
months) 
Italy F & M 11 2 and  3 2 doses up to 13/14 years of age. 
Three doses all other ages. Females 
in all regions, males included in 7 
regions  
Latvia F 12  Females only 
Liechtenstein F 11 and 15 2 Two doses. Females only. Catch-up 
vaccination  recommended before the 
20th birthday 
Lithuania     
Luxembourg F 12 and 15  Females only 
Malta F 12 3 For females born from the year 2000 
onwards. 3 doses in a 0, 1, 6 month 
schedule 
 
 
 
Netherlands F 12 2 For girls under age 15, 2vHPV can be  
administered in a 2 dose schedule 
instead of 3 previously. The 0-1-6-
schedule in under 15's is  
replaced by two doses in a 0-6-
schedule (40) 
Norway F 12 3 Females only. 7th grade Plan to 
maintain 3D 
Poland      
Portugal F 13 2 and 3 Three doses. Females only DGS 
10/2014: New vaccine schedule 
published with 2D and lowering age 
to 10-13 yrs 
Romania F 11 3 3 doses. Recommended, but not 
mandatory 
Slovakia F 12  Recommended only. Not included in 
the national immunization schedule. 
Partial reimbursement by the national 
healthcare system 
Slovenia F 11  Girls only 
 
 
 
 
Spain F 14 3 or 2 Three doses. Females only. 2D from 
Q3 2014 in some regions   
http://www.msssi.gob.es/profesionale
s/saludPublica/ 
prevPromocion/vacunaciones/docs/P
apilomaVPH.pdf 
Consejo Interterritorial 01/2015 - 
Common pediatric vaccination 
calendar Lowered age at 12yo (girls) 
Sweden Children  10 3 Three doses. Children. Social 
styrelsen Tvadoschema den 8 september 
2014 kl. 13:58 Nyhet children applies only 
to children 9-13 years: It must 
continue to be given to older children 
and adults, as well as 
immunosuppressed children 
Switzerland F 11 to 14 2 In the transition period also girls aged 
15 to 19 should be included (41). 
Switched from three dose to two dose 
vaccination schedules for girls aged 
9-14 years on the basis of such risk-
benefit considerations (40) 
UK F and 
MSM 
12 and 
16 to 40 
 
3 Females only. First dose can be 
given at any time during school year 
8, to girls who are usually 12 to 13 
years old. Second dose to be given 
around 12 months after the first. 
Implementing a catch-up  campaign 
of girls up to age 18 is likely to be  
cost-effective (40). 
Free of charge vaccination 3 doses 
for Males who have sex with Males 
(MSM)  up to 40 years of age (42) 
 
Cost-effectiveness studies of universal HPV vaccination present a small portion of the large 
data retrieved. Part of the information is excluded from most investigations including, but 
not limited to, impacts on productivity, patient’s time and costs, caregivers and family 
costs, and broader social values such as the right to access treatment. Consideration 
should be given to provide alternative approaches to capture a broader set of values in a 
way that might be useful to decisions-makers, such as multi-criteria decision analysis (43). 
However in the analysis of countries or regions the multi-parametric evaluations are not 
always based on comparable data.  
Jiang et alii conducted a critical review of available cost-effectiveness analysis for HPV 
vaccination in males and nine studies were identified from different countries. Key factors 
such as vaccine coverage rate and studies considered the epidemiological trend of HPV-
related diseases, such as the observed increase in the incidence of anal or head and neck 
cancers (44). Using 2011/2012 times and prices for England and Wales about 3000 
people had oropharyngeal cancer which cost approximately £115 million to treat. 70% of 
those cancers could reasonably be expected to be HPV driven. This equates to roughly 
£80 million in treatment costs. The all party UK parliamentarian health group estimated it 
would cost about £20-22 million to vaccinate boys in a gender neutral vaccination policy. 
Even at rough but reasoned estimates on Office for National Statistics (ONS) derived 
statistics and public domain Payment by Results (PbR) figures there is a fourfold saving 
for vaccinating just in financial terms (45,46).  
Official bodies including WHO and other supervisory authorities recommend that the 
decision-making process should be based on both the quality of goods and services as 
well as the analysis of the best achievable price, economic impact and cost-effectiveness 
(47).  
 
3.2. Cervical cancer treatment 
The combined use of administrative and clinical databases allowed assessing the costs 
relevant to cervical cancer. The management of patients affected by locally advanced 
cervical cancer (LACC) is associated with higher costs due to the utilization of several 
therapeutic strategies and a more frequent appearance of disease progression/recurrence. 
As far as treatment is concerned, patients with early stage cervical cancer are triaged to 
exclusive radiotherapy or radical surgery with comparable results in terms of clinical 
outcome, although with different rates of complications and severity of side effects (48). 
Although chemoradiation currently represents the gold standard in the treatment of locally 
advanced cervical cancer patients (49,50), the prognosis of this group of patients remains 
dismal, and there is still room for improving the treatment plan according to its different 
stages. Difficulties in assessing the formal cost of cervical cancer management is 
explained by the fact that clinical and administrative databases are often not linked. Some 
of the data has been collected analyzing patients diagnosis, treatment and follow-up in 
various (although similarly-organized) venues linked to the Italian Network of Cancer 
Registries: this has provided a comprehensive set of clinical and pathological information 
on characteristics and outcomes, with a relatively high degree of homogeneity (i.e.: 
diagnostic procedures, treatment protocols, surveillance etc…). Mean management costs 
(estimated by the International Federation of Gynecology and Obstetrics-FIGO) for 
incident cases (including 10 years of follow-up) were: € 6,024 (FIGO I); € 10,572 (FIGO II); 
€ 11,367 (FIGO III); € 8,707 (FIGO IV); and € 5,854 for the terminal phase (1 month) (51). 
Another analysis (48) pointed out that the mean cost by patient amounted in Italy to almost 
€ 29,000 and € 12,300 for a patient with locally advanced cervical cancer and early stage 
cervical cancer, respectively. As a different methodology was applied, these findings are 
hardly comparable with the results previously reported in studies conducted in other 
countries (such as the France, United Kingdom and United States) (52,53,54).  
 
3.3. Anogenital warts  
GWs event is highly variable in relation to its occurrence, management, and medical 
approach (general practice vs hospital-based dermatology, genitourinary, etc.). The annual 
cost in Italy of the treatment of genital warts is approximately € 37 million for females and 
about € 33 million for males (55). An economic analysis showed that the costs associated 
with GWs in men and women represented 24.3% (€ 70.9 million) of the total costs 
associated with HPV-6,-11,-16 and -18 diseases in Italy; preventing GWs and the 
associated costs alone would cover most of the costs for qHPV vaccination (55).  
 
3.4. Preventive measures  
In Italy, the Basilicata Region was the first to implement preventive measures in 2007; this was 
soon followed by other regions and provinces with different covering profiles in the following 
5 years. Based on a coverage rate of 80%, assuming lifetime duration of protection and 
discount rates of 1.5% and 3% for health benefits and costs respectively, the 
implementation of HPV vaccination in Italy among a cohort of girls aged 12 years has been 
evaluated to avoid 1,432 incremental cases of cervical cancer (−63.3%) and 513 related 
deaths (−63.4%) compared to screening program only (56). In this study, the impact of 
vaccination was evaluated considering the current screening strategy on women only. This 
evaluation provides estimates of cost-effectiveness for HPV vaccination in Italy which were 
consistent with data reported by another Italian study (57) highlighting similar conclusions 
on the cost-effectiveness of HPV vaccination alongside screening strategies in Italy, but 
with ICERs (incremental cost-effectiveness ratios) slightly higher (€ 34,676 per life year 
gained-LYG and € 26,361 per QALY gained). The main objective of the evaluation of the 
substantial burden of direct costs in the Italian National Health Service is to estimate the 
total direct medical costs associated with nine major HPV-related diseases, namely 
invasive cervical cancer, cervical dysplasia, cancer of the vulva, vagina, anus, penis, and 
head and neck, anogenital warts, and recurrent respiratory papillomatosis, and by 
providing an aggregate measure of the total economic burden attributable to HPV-6,-11,-
16, and -18 infection. The total direct costs (related to 2011) associated with annual 
incident cases of the nine HPV-related conditions included in the analysis were estimated 
to be € 528.6 million, with a plausible range of € 480.1–686.2 million. The fraction 
attributable to HPV-6, -11,-16, and -18 was € 291.0 (range € 274.5–315.7 million), 
accounting for approximately 55% of the total annual burden of HPV-related disease in 
Italy. The fraction of the total direct lifetime costs attributable to HPV-6,-11,-16, and -18 
infections and the economic burden of non cervical HPV-related diseases carried by men 
were found to be cost drivers relevant to the making of informed decisions about future 
investments in programs of HPV prevention (55).  
The difficulty of studying the pathophysiology of HPV in men is well addressed by 
Zuccotti et al (58). The authors show that there is a wide range of variability in the 
prevalence of the infection, related to the different methods of sampling used, the 
geographical area where the study was performed (in Europe and East Asia prevalences 
have been observed to be lower than in countries of the African continent), the anatomical 
site in which the virus has been researched, the number of sites considered in the study, 
the difficulty of having a population representative of the general population, and the risk 
group. Prue showed that the economic cost of HPV-related diseases is considerable and 
also that any decision about whether to vaccinate boys should not be based solely on cost 
effectiveness. Public health, equity, and the human costs of HPV-related disease for both 
sexes must be the main concern (59). The cost-effectiveness evaluation of vaccination is 
based also on the design of developed programs. Indeed, depending on the number (1, 2, 
or 3) of eligible cohorts, the cost of HPV vaccination in Italy might be assumed in a range 
between € 55 and € 120 million (60). On the other hand, annual costs associated with 
HPV-related diseases amount to about € 250 million (47). With the HPV vaccination, the 
overall reduction of HPV-related events over time would produce a total decrease in costs 
of approximately € 132 million (47). In order to optimize the use of public financial 
resources, a multi-cohort vaccination program should be considered in order to reach a 
positive balance point between the need to accelerate the cost reduction of the invasive 
cervical cancer and the rational management of healthcare demand. The PRIME 
(Papillomavirus Rapid Interface for Modelling and Economics) effectiveness model (61) 
developed to evaluate the impact on public health by the vaccination of 58 million girls (12 
years old) in 179 countries before their first sexual debut, would prevent 690.000 cases of 
cervical cancers and 400.000 linked deaths, with an estimated cost of US $ 4 billion. The 
current proposed and in some countries accepted two-dose vaccination with expected 
similar positive outcomes in terms of health efficacy and safety will hugely decrease the 
total cost.  
 
3.5. At European level  
The objective of the study of Marty et alii (62) was to estimate the incremental benefit of 
vaccinating boys and girls using the qHPV vaccine in Europe versus girls-only vaccination. 
Incremental benefits in terms of reduction in the incidence of HPV-6,-11,-16 and -18-
related diseases (including cervical, vaginal, vulvar, anal, penile, and head and neck 
carcinomas and genital warts) were assessed. Compared with screening alone, girls-only 
vaccination led to 84% reduction in HPV-16,-18-related carcinomas in females and a 61% 
reduction in males. Vaccination of girls and boys led to a 90% reduction in HPV-16,-18-
related carcinomas in females and 86% reduction in males versus screening alone. 
Relative to a girls-only program, vaccination of girls and boys led to a reduction in female 
and male HPV-related carcinomas of 40% and 65% respectively and a reduction in the 
incidence of HPV-6.-11-related genital warts of 58% for females and 71% for males versus 
girls-only vaccination.  
Further analyses should be performed taking into account the country-specific situation. In 
addition to clinical benefits, substantial economic benefits are also anticipated and warrant 
further investigation as do the social and ethical implications of including boys in 
vaccination programs (62). When talking about cancer as a preventable endpoint we have 
to question ourself twice if economic evaluation analysis of cost effectiveness is 
acceptable, the disease has an important economic and health impact in males with 
possible reduction of several thousand cases of anal cancer in males, this should be 
enough to justify male vaccination.  
 
3.6. Universal vaccination 
The economic impact of the gender-neutral vaccination has been assessed through 
several studies (43) focusing on the health prevention. Unfortunately several investigations 
fail to take into consideration the impact on the family costs to save presence of the person 
within the labor areas, and social values. The Bayesian model has been largely evaluated 
(63): the results confirm that the universal vaccination against HPV is cost-effective in 
comparison to the screening and the vaccination only of the women cohorts. Other studies 
have evaluated the effects of herd immunity and other variables (such as number of 
partners, smoking, and socio-cultural levels) and the potential of the universal vaccination 
has been confirmed (63). The principle of equity and equal access to healthcare to 
maximize a population's health is a cornerstone for all health systems, therefore universal 
vaccination would give men and women the same rights to protection. Targeting both boys 
and girls, in through routine universal HPV vaccination, would: 
• protect females and males against HPV-related cervical, vulvar, vaginal and anal 
(pre)cancers, and genital warts and, significantly reduce the remaining burden in both 
genders (62); 
• accelerate the control of HPV vaccine types circulation and related cancers and diseases 
with quasi-elimination of vaccine HPV strains in the population (64,65,66); 
• normalize HPV vaccination to become a standard vaccination in pre-adolescents; 
• reduce gender and social health inequalities by protecting men exposed to unvaccinated 
female or male partners (increased risk with population movements) and protecting the 
most vulnerable people. 
It has been estimated that universal HPV vaccination programs can significantly reduce 
the remaining burden of HPV-vaccine types related (pre)cancers and genital warts in both 
females and males, as also shown by internal modelling exercise based on a European 
adaptation of the Marty et alii model (Fig. 1.-2.-3.) 
 
 
Fig 1.: Estimate of the reduction of the remaining HPV-16,-18-
GENITAL and ANAL CANCERS burden in FEMALES in Europe 
through female-only HPV vaccination and universal HPV 
vaccination (age 12yo, 70% VCR) 
 
Fig 2.: Reduction of the remaining HPV-16,-18-ANAL CANCER 
burden in FEMALES and MALES in Europe through female-only 
HPV vaccination and universal HPV vaccination (age 12yo, 70% 
VCR) 
 
Fig 3.: Reduction of the remaining HPV-6,-11-GENITAL WARTS burden in FEMALES and MALES in Europe through  
female-only vaccination and universal vaccination (excluding HPV-related head/neck cancers) (age 12yo, 70% VCR) 
 
As already discussed, HPV vaccination is a highly valuable investment which contributes 
to more sustainable and efficient health systems with economic benefits. Incremental cost-
effectiveness ratios are generally lower for the quadrivalent vaccine versus the bivalent 
vaccine, mainly due to additional benefits of genital wart prevention (67). The full economic 
benefits of HPV vaccination are difficult to be quantified in monetary terms (e.g.: decrease 
-39% 
-64% 
-43% 
-71% -58% 
of the burden for the caregiver, psychosocial impact, impact on fertility, productivity loss) 
and therefore the cost-effectiveness is likely not to be the most relevant measure, based 
on existing guidelines, when assessing the broad economic value of HPV universal 
vaccination (43). At a national and European level it is observed that:  
• on the short-run, an early return on investment is observed due to the prevention of 
genital warts with 4vHPV vaccination with the majority of costs saved over the 5 to 10 
years following vaccination due to genital warts prevention (68); 
• on a long-term basis, a broad benefit-cost analysis in Germany showed that universal 
HPV vaccination (1 cohort of 12-year-old girls and boys) resulted into a positive net 
economical value. Every Euro spent on universal vaccination provides € 1.81 of 
revenue to the government (69). 
It is important to underline that HPV vaccination represent a low-cost and efficient 
intervention for HPV-related cancers not only in comparison with other oncologic 
treatments. It also represents a sustainable solution thanks to its long term duration of 
protection. 
4. Are there new political positions in the prevention of HPV 
infection? 
4.1. Upgraded positions 
In 2012 about 40 countries (22 in Europe, 6 in the Americas, 1 in Eastern Mediterranean, 
10 in Western Pacific, 1 in South East Asia, and 1 in Africa) were delivering immunization 
programs against HPV, although with different approaches, with a starting target group of 
girls at 11 or 12 years of age and with variable catch up group till 26 years of age. USA 
and Austria had started in 2006, and Sweden entered the group in 2012. Worldwide the 
delivery of the vaccination was carried out either in the schools or in health centers. By 
August 2014, 58 countries have had introduced HPV vaccine in their national 
immunization programs for girls, and in some countries also for boys (13). The European 
Medical Agency in 2011 introduced boys/men in the HPV target but limited to genital 
areas; some European countries started with a vaccination aimed at men, delivering it free 
of charge to young male people; during 2014 in Italy as of today, 6 regions out of 21 have 
decided to include free males active vaccination. The qHPV vaccine has been approved 
for the prevention of anal cancer in June 2014. The qHPV vaccine, which includes HPV-6 
and HPV-11, the HPV types that most commonly cause ano-genital warts, when given in a 
3-dose schedule provides high-level protection against anogenital warts in males and 
females and anogenital precancerous lesions in susceptible males aged 16–26 years. 
Some studies in high income settings have reported that vaccinating adolescent girls for 
cervical cancer prevention might potentially be cost-effective if vaccine coverage in girls is 
high. Other investigations in high-income settings (Norway) have reported that expanding 
the HPV vaccination programs to boys, may be cost-effective and may warrant a change 
in the current female-only vaccination policy in the country (70). In vaccinees who were 
seronegative in the vaccines currently employed, high seroconversion rates and high 
levels of anti-HPV antibodies against HPV-6 and HPV-11 virus-like particles were 
observed in females aged 9-45 years and in males aged 9-26 years (71). In a number of 
industrialized countries (Australia, Sweden, Denmark and the United States of America) 
substantial decreases in cases of genital warts have been observed following the 
introduction of a national HPV vaccination program using qHPV vaccine (28). From 
analyzing eighteen studies including between 897 and 46.900 women, De Vuyst et alii 
have demonstrated that in female the prevalence of HPV is high in the first years of the 
sexual debut and lowers later on, while in male it remains high throughout life (72). A 
comprehensive cost analysis should capture the full economic value of vaccination 
management programs in both genders including the quality-adjusted life-year gained in 
several cohorts. In health care this approach is a non ending evolutionary process that 
creates a new responsibility for decision-making choices globally (73). 
 
4.2. Incremental cost of HPV vaccination 
The analysis of incremental cost of HPV vaccination in women protection against cervical 
cancer opens a series of questions marks. The reported data from the literature show a 
different economic interpretation in the mentioned countries (see Table 4.) of a substantial 
answer to a correct interpretation of the concepts on health rights 
(74,65,75,76,56,77,78,79,80). 
 
 
 
Legenda: QALY quality-adjusted life years. ICER QV incremental cost-effectiveness ratio. 
TPP: third-party payer perspective quality-adjusted life-year. DCP direct healthcare cost 
perspective for quality-adjusted life-year for Data.  
Published studies on cost effectiveness of HPV vaccination suggest that vaccination 
against HPV can be used and can be cost effective. Over 64 countries around the world 
were included in cost effectiveness analyses of HPV vaccination (81). In this study the 
mean value of ICER was $ 28,399, with a median $ 15,600. Data on men are not sufficient 
and not comparable to data on women in the cervical cancer. The studies included in this 
mentioned review used different methodologies and had various assumptions but were 
consistent in the conclusion that preadolescent female vaccination is cost effective 
compared to screening alone. Values of cost effectiveness ratios are not static and can 
change in time. It is clear that the evaluation changes from country to country.  
In the United Kingdom and in Italy, with competitive tendering, tender prices for vaccines 
can be substantially lower than their list price. 
The recent introduction in some countries (such as United Kingdom and Italy) of the two 
doses vaccination schedule is opening questions on the long lasting protection against 
infection, and that means that the cohorts given two doses should  be monitored (40). This 
approach is asking more studies with the introduction of the 9vHPV vaccine.  
An economic evaluation is expected to assess the cost-effectiveness of the introduction of 
boys in the vaccination schedules.  
During its February 2015 meeting, the Advisory Committee on Immunization Practices 
(ACIP) recommended 9-valent human papillomavirus (HPV) vaccine (9vHPV) as one of 
three HPV vaccines that can be used for routine vaccination (82). This introduction is 
proposing a new evaluation of the HPV vaccine use within the countries. 
In this mutable scenario the added long term value for public policy purposes remains 
untested: the use of forecasting models is limiting the uncertainty of assumptions, although 
it is not comparable to long term epidemiological studies (83). 
5. Conclusions 
Epidemiological data show how HPVs affect both men and women, with men carrying a 
considerable burden of disease, enough to justify amendments of the national 
recommendations for immunization programs against HPV-associated lesions. There is an 
increasing opportunity to decrease the burden of the disease and to increase quality of life 
(81), taking advantage of the increasing opportunity to reduce HPV infection and its 
transmission among sexual partners, as much as of the strong evidence in favour of the 
efficacy and effectiveness of HPV vaccines in preventing the development of HPV-related 
diseases. 
The cost-effectiveness of including boys into HPV vaccination programs should be re-
assessed in every country in view of the progressive drop of the economic burden of HPV-
related diseases in men and women due to universal vaccination. These achievements 
demand urgent attention to the social equity for both genders in healthcare (84); 
advocating and educating the general public and the medical community on HPV 
vaccination is a top priority (85). 
Unfortunately the organization and quality of HPV vaccination programs differ across 
countries and, in some instances, even across regions within the same country. The 
majority of countries had some level of vaccination activity, and half of them report an 
organized vaccination program. Costs of organization and monitoring are difficult to 
estimate and varied significantly. In many cases it is difficult to compare systems and 
infrastructures among them, as some countries were able to use existing infrastructures 
while others had to create new systems, incurring greater costs (86). The cost of 
organization is a point of large discussion not only in Europe (87,88).  
The comparison of the different approaches among European countries confirms the need 
to develop and implement a common policy of HPV vaccination within the frame of the 
concept of a "one only" European health system. From the above-mentioned evaluations it 
is clear that, thanks to HPV vaccination, the economic management of related tumor 
prevention must be seen in a larger European context, rather than in a single region or a 
single country. The importance of HPV related diseases is recognized by WHO, which 
considers the prevention of cervical cancer and/or other HPV-related diseases as a public 
health priority, through the programmatically feasible introduction of HPV vaccine. 
However, WHO so far has not been able to secure a sustainable financing and to 
implement cost-effective vaccination strategies in most countries or regions (13). The 
following strategy suggested by WHO should become an urgent executive policy for the 
European Union including: education about reducing behaviors that increase the risk of 
acquiring HPV infection; training health workers and providing information to men and 
women on screening, diagnosis and treatment of HPV associated tumors. HPV 
vaccination should be considered as a primary prevention tool, although it does not 
eliminate the need for further screening later in life, since currently available vaccines do 
not protect against all high risk HPV types. 
The full effect of HPV vaccination is expected to be seen only in 30-40 years time (89). 
Given the future of a heterogenous target population it would be reasonable to replace the 
“one-model-fits-all” today screening schedule with stratified algorithms. The introduction of 
2-doses, as it is going to be in some countries in Europe, will open a new evaluation of the 
cohort and screening programs selection. The European healths authorities (EMA) have 
licensed the bivalent and quadrivalent vaccines for a 2-dose application with suggested 
interval with 6 to 12 months (90). The future of cervical cancer screening is linked to the 
modification of screening programs where the HPV-DNA testing will be added or will 
substitute the Papanicolau testing or co-testing. In USA the primary HPV screening is 
considered to be an alternative of the Papanicolau testing or co-testing. The Netherlands 
and Australia plan to replace Papanicolau testing with primary HPV testing in 2016 (90). 
This changing will ask a confirmation by the general implementation of the HPV-DNA tests 
that are modifying the traditional HPV screening through cytology. In this field the scientific 
results are expected to confirm or modify the today approach in the vaccination policies 
within the countries.  
The European Union is asked to equally spread support across all country members in: 
reaching cost-effective vaccination programs in boys and girls; delivering affordable control 
policies of the results of the vaccination programs; empowering the population in 
defending their health values in front of HPV linked diseases. If countries consider phased 
introduction, priority should be given to strategies that include those European populations 
who are likely to receive less access to screening for cervical cancer later in life. With 
currently effective vaccines, the focus of organized HPV vaccination programs should 
change from the reduction of HPV disease burden to the control of high-risk HPV and low-
risk HPV types (14). There is sufficient ethical, scientific, strategic and economic reasons 
to urge the European Community to develop and implement a coordinated and 
comprehensive strategy aimed at both genders and geographically balanced, to eradicate 
cervical cancer and other diseases caused by HPV in Europe.  
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Efficacy of vaccines 
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14. J Nat Rev Clin Oncol 2013; 10: 400-410; 
18. J Natl Cancer Inst 2012; 104: 1712-1723; 
19. Infectious Agents and Cancer 2012; 7:38. 
 Target HPV-6,-11-16,-18 infection Efficacy (%) 
CIN 2/3 98.2 
VIN 2/3 100 
VaIN 2/3 100 
Female 16-26 
years 
Genital warts 99.0 
Female 24-45 
years 
CIN, LGE 95.7 
LGE 90.4 
Quadrivalent 
Males 16-26 
years  AIN 77.5 
CIN 2+ 94.9 
Bivalent 
Female 15-25 
years CIN 3+ 91.7 
 
 
Table 2. 
HPV vaccines control  by the WHO Global Advisory Committee on Vaccine Safety (GACVS) 
(29,30,13) 
When Starting Points Issues Statement 
GACVS update on 
HPV Vaccines  
19 July 2013 (29) 
 
In 2013 GACVS noted that  
growing evidence on the 
safety of HPV vaccines 
was reassuring; studies on 
HPV immunization had 
started, along with 
capacity-building for 
adverse events 
monitoring. GACVS places 
a high priority on the 
ongoing collection of high-
quality safety data in 
settings where the vaccine 
is being introduced. 
4 years after the last review of 
HPV vaccine safety and with 
more than 170 million doses 
distributed worldwide and 
more countries offering the 
vaccine through national 
immunization programs, the 
Committee continues to be 
reassured by the safety profile 
of the available products. 
A timely clinical assessment 
and diagnosis of each case 
followed by appropriate 
treatment is therefore 
essential. 
GACVS Statement 
on the continued 
safety of HPV 
vaccination 
March 12, 2014 (30) 
 
 
As with all new vaccines, the 
GACVS has been reviewing 
the safety of HPV vaccines 
since they were first licensed 
in 2006. 
Safety concerns about HPV 
vaccines have systematically 
been investigated: to date, the 
GACVS has not found any 
safety issue that would alter 
any of the current 
recommendations for the use 
of the vaccine and its 
introduction is 
programmatically feasible. 
It is important to highlight 
and reiterate this work 
because a number of 
national immunization 
programs have been facing 
real and potential public 
losses of confidence in their 
programs as a result of 
increased negative publicity, 
even from safety issues that 
have been addressed  
WHO Weekly 
epidemiological 
record 
24 October 2014 (13) 
 
 
WHO recognizes cervical 
cancer and other HPV-related 
diseases as global public 
health problems and 
reiterates its recommendation 
that HPV vaccines should be 
included in national 
immunization programs. 
Prevention of cervical cancer 
and/or other HPV-related 
diseases constitutes a public 
health priority; vaccine 
introduction is 
programmatically feasible; 
sustainable financing can be 
secured; and the cost-
Both the quadrivalent 
and bivalent HPV vaccines 
have excellent safety and 
efficacy profiles. 
 effectiveness of vaccination 
strategies in the country or 
region is considered. 
 
 
Table 4.Incremental cost of HPV vaccination in women protection against cervical 
cancer   
Austria € 26,701 QALY 
Belgium  € 10,546 QALY  
France € 8,408   QALY  per TPP or 13,809 per DCP 
Germany € 10,530 QALY 
Hungary $ 27,588 QALY 
Italy € 9,569 ICER per QALY 
Netherlands € 53 500 QALY  
5,815 ICER per QALY 
Norway € 8,272 QUALY 
Slovenia  € 23,178 ICER per QALY  
Switzerland CHF 26,005 ICER per QALY 
UK £ 21,059 ICER per QALY 
varying discount rates from 3,5% for medical benefits to 1,5% 
would decrease the ICER to £9,653 per QALY. 
 
